Cerevance scores $45m Series B

Cerevance, a private drug discovery and development company focused on brain diseases, has raised $45 million in Series B financing.

Cerevance, a private drug discovery and development company focused on brain diseases, has raised $45 million in Series B financing. The investors included GV, Bill Gates, Foresite Capital, Takeda Ventures Inc, the Dementia Discovery Fund and Lightstone Ventures.

Source: Press Release